All patients (n=2293) | Men (n=1441) | Women (n=852) | |
Age, mean (SD) (years) | 59.88(10.61) | 58.24(10.79) | 62.64(9.69)* |
60-64 | 450(19.6%) | 269(18.7%) | 181(21.2%) |
65-74 | 628(27.4%) | 348(24.1%) | 280(32.9%) |
≥75 | 175(7.6%%) | 79(5.5%) | 96(11.3%) |
Persistent AF | 870(37.9%) | 599(41.6%) | 271(31.8%)* |
AF duration (months)# | 36.17(39.08) | 34.27(38.06) | 39.40(40.57)* |
Congestive heart failure | 43(1.9%) | 27(1.9%) | 16(1.9%) |
Hypertension | 1125(49.1%) | 661(45.9%) | 464(54.5%)* |
Diabetes mellitus | 371(16.2%) | 221(15.3%) | 150(17.6%) |
Prior stroke/TIA/systemic embolism | 226(9.9%) | 139(9.6%) | 87(10.2%) |
Vascular disease | 488(21.3%) | 261(18.1%) | 227(26.6%)* |
CHA2DS2-VASc score, mean (SD) | 1.88(1.56) | 1.36(1.34) | 2.77(1.50)* |
Triglyceride glucose index | 8.56(0.56) | 8.56(0.55) | 8.57(0.57) |
HAS-BLED score, mean (SD) | 0.51(0.66) | 0.45(0.64) | 0.61(0.68)* |
Renal disease | 2(0.1%) | 2(0.1%) | 0(0%) |
Liver disease | 13(0.6%) | 7(0.5%) | 6(0.7%) |
Anemia | 13(0.6%) | 2(0.1%) | 11(1.3%)* |
Alcohol consumption | 520(22.7%) | 511(35.5%) | 9(1.1%)* |
Body mass index, kg/m2, mean (SD) | 26.19(3.55) | 26.33(3.31) | 25.95(3.92)* |
LAD 40 -50mm | 988(43.1%) | 634(44.0%) | 354(41.5%) |
>50mm | 153(6.7%) | 108(7.5%) | 45(5.3%) |
Cryoballoon ablation | 149(6.5%) | 83(5.8%) | 66(7.7%) |
Non-PV ablation | 1070(46.7%) | 734(50.9%) | 336(39.4%)* |
Observational period prescription | |||
Non-vitamin k oral anticoagulants | 2028(88.4%) | 1271(88.2%) | 757(88.8%) |
Warfarin | 248(10.8%) | 164(11.4%) | 84(9.9%) |
Antiplatelet drugs | 367(16.0%) | 236(16.4%) | 131(15.4%) |
ACEI/ARB | 568(24.8%) | 335(23.2%) | 233(27.3%)* |
Statins | 662(28.9%) | 395(27.4%) | 267(31.3%)* |
Follow-up duration, mean(SD) (months) | 50.36(19.65) | 50.70(19.62) | 49.78(19.69)* |
AF recurrence | 575(25.1%) | 330(22.9%) | 245(28.8%)* |
Cardiovascular rehospitalization | 351(15.3%) | 204(14.2%) | 147(17.3%)* |
Major cardiovascular and cerebrovascular events | 141(6.1%) | 83(5.8%) | 58(6.8%) |
New stroke/TIA/systemic embolism | 75(3.3%) | 42(2.9%) | 33(3.9%) |
Acute myocardial infarction | 18(0.8%) | 13(0.9%) | 5(0.6%) |
Advanced heart failure | 13(0.6%) | 3(0.2%) | 10(1.2%)* |
Major bleeding | 2(0.1%) | 1(0.1%) | 1(0.1%) |
Deaths | 48(2.1%) | 32(2.3%) | 16(1.9%) |
Long-term prescription | |||
Oral anticoagulants | 438(19.1%) | 275(19.1%) | 163(19.1%) |
Antiarrhythmic drugs | 247(10.8) | 154(10.7%) | 93(10.9%) |
Antiplatelet drugs | 742(32.4%) | 449(31.2%) | 293(34.4%) |
ACEI/ARB | 793(34.6%) | 479(33.2%) | 314(36.9%) |
Statins | 924(40.3%) | 548(38.0%) | 376(44.1%)* |
Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex category (female); HAS-BLED, hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs or alcohol concomitantly; LAD, left atrial diameter; ACEI, angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blockers; PV, pulmonary vein | Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex category (female); HAS-BLED, hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs or alcohol concomitantly; LAD, left atrial diameter; ACEI, angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blockers; PV, pulmonary vein | Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex category (female); HAS-BLED, hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs or alcohol concomitantly; LAD, left atrial diameter; ACEI, angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blockers; PV, pulmonary vein | Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex category (female); HAS-BLED, hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs or alcohol concomitantly; LAD, left atrial diameter; ACEI, angiotensin converting enzyme inhibitors; ARB, Angiotensin receptor blockers; PV, pulmonary vein |
P<0.05, compared with men; # since first diagnosis | * P<0.05, compared with men; # since first diagnosis | * P<0.05, compared with men; # since first diagnosis | * P<0.05, compared with men; # since first diagnosis |